Brokerages Set Kezar Life Sciences, Inc. (NASDAQ:KZR) Price Target at $6.00

Kezar Life Sciences, Inc. (NASDAQ:KZR) has received an average recommendation of “Reduce” from the six analysts that are covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation and four have issued a hold recommendation on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $6.00.

Institutional Trading of Kezar Life Sciences

Several large investors have recently bought and sold shares of the company. Geode Capital Management LLC grew its position in Kezar Life Sciences by 4.1% in the fourth quarter. Geode Capital Management LLC now owns 68,167 shares of the company’s stock valued at $429,000 after acquiring an additional 2,665 shares in the last quarter. Dimensional Fund Advisors LP grew its position in shares of Kezar Life Sciences by 14.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 26,543 shares of the company’s stock worth $167,000 after buying an additional 3,312 shares in the last quarter. State Street Corp grew its position in shares of Kezar Life Sciences by 28.4% during the fourth quarter. State Street Corp now owns 27,093 shares of the company’s stock worth $170,000 after buying an additional 6,000 shares in the last quarter. Bridgeway Capital Management LLC grew its position in shares of Kezar Life Sciences by 25.9% during the fourth quarter. Bridgeway Capital Management LLC now owns 51,638 shares of the company’s stock worth $325,000 after buying an additional 10,638 shares in the last quarter. Finally, Peapod Lane Capital LLC grew its position in shares of Kezar Life Sciences by 9.3% during the third quarter. Peapod Lane Capital LLC now owns 125,773 shares of the company’s stock worth $491,000 after buying an additional 10,650 shares in the last quarter. Institutional investors and hedge funds own 67.90% of the company’s stock.

Kezar Life Sciences Stock Down 1.0%

Shares of NASDAQ:KZR opened at $7.29 on Tuesday. Kezar Life Sciences has a 52-week low of $3.53 and a 52-week high of $7.55. The company has a 50 day moving average of $7.09 and a two-hundred day moving average of $6.55. The company has a market capitalization of $53.87 million, a price-to-earnings ratio of -0.95 and a beta of 0.40.

Kezar Life Sciences (NASDAQ:KZR) last issued its quarterly earnings data on Friday, March 27th. The company reported ($1.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.39) by ($0.60). On average, equities analysts anticipate that Kezar Life Sciences will post -3.58 earnings per share for the current year.

About Kezar Life Sciences

Kezar Life Sciences is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapies that modulate the innate immune system. The company’s research centers on selective inhibition of the immunoproteasome, a key protein complex involved in antigen processing and secretion of inflammatory cytokines. By targeting this pathway, Kezar aims to address unmet medical needs in autoimmune and inflammatory diseases with high specificity and a favorable safety profile.

The company’s lead development candidate, KZR-616, is a selective immunoproteasome inhibitor being evaluated in multiple clinical trials for autoimmune conditions such as systemic lupus erythematosus, lupus nephritis, polymyositis and dermatomyositis.